Comparison of Efficacy and Safety Between Dronedarone and Amiodarone Used During the Blind Period in Patients with Atrial Fibrillation After Catheter Ablation

Figures & data

Table 1 Baseline Characteristics of Participants According to Group

	All Patients (n=431)	Amiodarone Group (n=202)	Dronedarone Group (n=229)	p-value
Male	267(61.9%)	129(63.9%)	138(60.3%)	0.442
Age, years	59.46±10.20	59.02±9.54	59.84±10.76	0.125
Paroxysmal atrial fibrillation	334(77.5%)	147(72.8%)	187(81.7%)	0.027
BMI (kg/m^2)	26.59±3.32	26.72±3.50	26.48±3.17	0.086
CHA2DS2-VASC score	1.53±1.23	1.50±1.19	1.57±1.27	0.543
HAS-BLED score	0.90±0.78	0.87±0.76	0.94±0.79	0.336
Coronary heart disease	123(28.5%)	54(26.7%)	69(30.1%)	0.436
Diabetes	57(13.2%)	26(12.9%)	31(13.5%)	0.839
High blood pressure	224(52.0%)	102(50.5%)	122(53.3%)	0.564
Smoking	99(23.0%)	74(36.6%)	25(10.9%)	<0.001
Drinking	80(18.6%)	54(26.7%)	26(11.4%)	<0.001
Glu (mmol/L)	5.24±1.45	5.23±1.57	5.25±1.33	0.367
TC (mmol/L)	4.08±1.02	4.22±1.05	3.96±0.97	0.107
TG (mmol/L)	1.20(0.92,1.77)	1.24(0.95,1.85)	1.17(0.89,1.64)	0.071
HDL (mmol/L)	1.15±0.27	1.14±0.27	1.15±0.27	0.623
LDL (mmol/L)	2.51±1.20	2.66±1.41	2.38±0.96	0.026
HGB (g/L)	142.09±17.44	143.92±17.41	140.48±17.34	0.392
INR	1.20±0.53	1.24±0.64	1.17±0.41	0.009
FT3 (pmol/L)	4.49(4.14,5.06)	4.55(4.06,5.00)	4.62(4.21,5.15)	0.080
FT4 (pmol/L)	15.99±3.26	15.89±2.84	16.07±3.59	0.051
LA (mm)	41.52±5.99	42.20±6.21	40.92±6.21	0.296
LVEF (%)	0.62±0.08	0.61±0.08	0.63±0.07	0.058
NOAC(%)	420(97.4%)	199(98.5%)	221(96.5%)	0.187
β-receptor blocking drugs	169(39.2%)	89(44.1%)	80(34.9%)	0.053
CCB	47(10.9%)	23(11.4%)	24(10.5%)	0.763
Antiplatelet drugs	22(5.1%)	9(4.5%)	13(5.7%)	0.565
ACEI/ARB	133(30.9%)	61(30.2%)	72(31.4%)	0.780
Statins	200(46.4%)	95(47.0%)	105(45.9%)	0.807

Notes: Continuous variables were expressed as mean (SD) in case of Normal distribution or medians and inter-quartile ranges in case of non-Normal distribution.

Abbreviations: BMI, body-mass index; Glu, glucose; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; HGB, hemoglobin; INR, international normalized ratio; FT3, free triiodothyronine; FT4, free thyroxine; LA, left atrium; LVEF, left ventricular ejection fraction; NOAC, new oral anticoagulants; CCB, calcium channel blockers; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotension II receptor blockers.

Table 2 The Recurrence Rate of Atrial Fibrillation in the Dronedarone Group and Amiodarone Group

		The Recurrence Rate of AF in Long-Term			The Recurrence Rate of AF in Blanking Period
	Total	n	HR(95% CI)	p-value	n	HR(95% CI)	p-value
Unadjusted model
Amiodarone	202	43	Reference		20	Reference
Dronedarone	229	52	0.962(0.642,1.444)	0.853	33	0.694(0.398,1.211)	0.199
Adjusted model
Amiodarone	202	43	Reference		20	Reference
Dronedarone	229	52	1.033(0.661,1.614)	0.888	33	0.851(0.463,1.564)	0.604

Abbreviations: AF, atrial fibrillation; HR, hazard ratio; 95% CI, 95% confidence interval.

Figure 1 Kaplan–Meier survival curve of sinus rhythm maintenance rate by different groups.

Figure 2 Multivariate cox analysis of recurrence rate of atrial fibrillation.

Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; BMI, body mass index; HBP, high blood pressure; CHD, coronary artery disease; Glu, glucose; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; FT3, free triiodothyronine; FT4, free thyroxine; LA, left atrium.

Figure 3 Subgroup analyses for the primary outcome.

Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; BMI, body mass index; HBP, high blood pressure; CHD, coronary artery disease; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; LA, left atrium.

Figure 4 Adverse drug events occurred in dronedarone group and amiodarone group.

Abbreviation: p, p-value.